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Abstract
Background: Though breast cancer remains a major health problem, there is a lack of information on health care
provided to patients with this disease and associated costs. In addition, there is a need to update and validate risk
stratification tools in Spain. Our purpose is to evaluate the health services provided for breast cancer in Spain, from
screening and diagnosis to treatment and prognosis.
Methods: Prospective cohort study involving 13 hospitals in Spain with a follow-up period of up to 5 years after diagnostic
biopsy. Eligibility criteria: Patients diagnosed with breast cancer between April 2013 and May 2015 that have consented to
participate in the study. Data collection: Data will be collected on the following: pre-intervention medical history, biological,
clinical, and sociodemographic characteristics, mode of cancer detection, hospital admission, treatment, and outcomes up to
5 years after initial treatment. Questionnaires about quality of life (EuroQoL EQ-5D-5 L, the European Organization For Research
And Treatment Of Cancer Core Quality Of Life Questionnaire EORTC QLQ-C30 join to the specific breast cancer module
(QLQ-BR23), as well as Hospital Anxiety and Depression Scale were completed by the patients before the beginning of
the initial treatment and at the end of follow-up period, 2 years later. The end-points of the study were changes in health-
related quality of life, recurrence, complications and readmissions at 2 and 5 years after initial treatment. Statistical analysis:
Descriptive statistics will be calculated and multivariate models will be used where appropriate to adjust for potential
confounders. In order to create and validate a prediction model, split validation and bootstrapping will be performed.
Cost analysis will be carried out from the perspective of a national health system.
Discussion: The results of this coordinated project are expected to generate scientifically valid and clinically and socially
important information to inform the decision-making of managers and the authorities responsible for ensuring equality in
care processes as well in health outcomes. For clinicians, clinical prediction rules will be developed which are expected to
serve as the basis for the development of software applications.
Trial registration: NCT02439554. Date of registration: May 8, 2015 (retrospectively registered) .
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Background
Prevalence of breast cancer remains high worldwide [1].
Mortality rates have been decreasing since the 1970s.
Screening programs and advences in adyuvant therapy
have contributed to decrease mortality and this pathology
has become in a chronic disease. l [2]. On the other hand,
the development of new biomarkers and other diagnostic
tools and new therapies could lead to a greater variability
in clinical practice.
Several decision tools have already been created with
the aim of predicting overall 5 or 10 year and disease-
free survival [3–5]. In addition, with the increase in the
life-expectancy in these women, it has become import-
ant to assess quality of life [6–8]. On the other hand, the
course of breast cancer may be influenced by variables
not directly related to the breast, such as other comor-
bidities and treatments [9–11].
This research was designed under the auspices of the
Health Services Research on Chronic Patients Network
(REDISSEC). This network was created to focus on three
major issues: the challenge of managing the phenomenon
of chronicity, the desire for more and better information,
and a need to increase research capacity in the fields of
health policies and services in Spain [12]. The overall
objective of the CAMISS (abbreviation from the Spanish
for health services research in breast cancer) research pro-
ject is to evaluate the health services received by patients
with breast cancer from screening, diagnosis and treatment
to prognosis (complications, survival, and quality of life).
Sala et al. conducted the CAMISS-Retrospective study,
which included 1086 women with breast cancer from a
population-based screening program. These women were
diagnosed with breast cancer between 2000 and 2008 and
were followed-up to December 2013. The main objective
of that study was to assess the impact of the mode of de-
tection (screen-detected cancer vs. interval breast cancer)
on overall survival and disease-free survival. Notably,
however, symptomatic women were not included in this
retrospective cohort and data were not collected on qual-
ity of life [13].
The CAMISS-Prospective study was designed by REDIS-
SEC researchers in an effort to provide information on: 1)
outcomes and their variability in breast cancer; 2) potential
tools to improve the decision-making process from health
system, professional and patient perspectives; and 3) the
costs related to breast cancer in Spain. Our goal in this
paper is to explain the design of the CAMISS-Prospective
study, the second part of a comprehensive evaluation of
health services research in patients with breast cancer in
Spain. To our knowledge, this is the first research with this
comprehensive perspective in Spain, considering not only
clinical and economic outcomes but also in patient-reported
outcomes. We will also combine retrospective data (from the
CAMISS-Retrospective study) with this prospective research.
Methods/Design
Aim
The specific study objectives (which are set out in detail in
Table 1) are, in brief: 1. to assess outcomes related to a)
process of care (early diagnosis, access to health care and
screening programs, delays in diagnosis, and variability in
treatments), and b) patients (sociodemographic and clinical
characteristics, including biomarkers, and patient-reported
outcomes, such as quality of life and emotional state); 2. to
create and validate prediction models (for changes in qual-
ity of life, relapse and death); and 3. to assess the costs asso-
ciated with breast cancer care and its potential variations
between Spanish regions.
Design and setting
CaMISS-Prospective is an observational analytic prospect-
ive cohort study. All the patients have been consecutively
selected between April 15, 2013 and May 20, 2015, from 13
hospitals in 4 Spanish regions (Andalusia, Canary Islands,
Catalonia, and the Basque Country). All participant centers
belongs to the Spanish National Services were primary care
and hospital emergency departments are free. Regions and
participating hospitals are listed in Table 2.
Table 1 Objectives
1. Outcomes assessment 2. Creation of predictive models 3. Health services evaluation
in breast cancer patients
in Spain
To describe and analyse variability in outcomes by
mode of detection, hospital, region and surgeon
• To create and validate predictive rules for relapse, mortality
and complications
• To estimate the average costs
of breast cancer care in Spain
To describe and analyse variability in the
diagnostic process and treatment
• To identify risk factors for poor health-related quality of
life 2 years after treatment
• To investigate differences
between Spanish regions
To explore potential inequalities by age, education
and socioeconomic level
• To validate our predictive rules for relapse, mortality and
complications in a retrospective sample of patients from
early detection programs
• To identify the most efficient
process and treatments in
breast cancer
To evaluate the impact of first hospital care
(urgent or scheduled) and of delays on relapse,
metastasis and death
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Study population
Women older than 18 years with an incident breast tumor
will be included. The breast cancer diagnosis considered
will be that reached after a biopsy of the tumor, including
cases of ductal carcinoma in situ, invasive ductal carcin-
oma, tubular carcinoma, mucinous carcinoma, papillary
carcinoma, cribriform carcinoma, invasive lobular carcin-
oma and lobular carcinoma in situ.
Symptomatic breast cancer will be included, as well as
screened and interval breast cancer. The breast cancer
screening program is public and universal in Spain. Follow-
ing the recommendations of the European Guidelines for
Quality Assurance in breast cancer screening and diagnosis
[14], the Spanish Breast Cancer Screening Program pro-
vides free biennial screening to women who are between 50
and 69 years old. Recently, women aged from 45 to 49 years
and 65 to 69 years are being incorporated into screening
programs. Interval breast cancer is defined as primary
breast cancer diagnosed in a woman who had a screening
test, with or without further assessment, with a negative
result, and diagnosed well before the next invitation to the
screening test or before a period of time equal to the
screening interval in a woman who has reached the upper
age limit for screening [15].
Exclusion criteria are: diagnosis of sarcoma, lymphoma
or inflammatory carcinoma; breast cancer recurrence; ter-
minal illness; and a severe mental or physical condition or
any other factor which interferes with the woman’s ability
to complete the questionnaires. In addition, in situ carcin-
omas will be excluded from the survival analysis.
Socio-demographic and clinical data will be collected on
women lost to follow-up. Figure 1 represents flow-chart of
the recruitment and Table 2 represents data collection in
participant centers.
Information and data collection
Eligible patients are to be selected from the surgery lists if
surgery is indicated or, when neoadjuvant therapy is the
first treatment given, from the lists for oncological treat-
ment. Patients are contacted by phone and informed of
the study objectives and, if they agree to participate, asked
to provide written informed consent.
Our goal is to follow-up participants for 5 years from the
confirmation biopsy. Figure 2 summarizes the data collec-
tion process. Clinical and personal data will retrieved from
medical records by trained reviewers before admission, and
at 2 and 5 years after diagnosis. Information on hospital
characteristics has been provided by the management of
each hospital. In order to collect data on health-related
quality of life, patients will be contacted to complete ques-
tionnaires administered by trained interviewers after their
first treatment and at 2 years. The first interview is to be
performed in the period between diagnosis and the date of
surgery or the beginning of the neoadjuvant therapy in the
cases in which this therapy is the first option. At 2 years,
patient-reported outcomes will be self-reported by mail or
through self-administered questionnaires completed during
a follow-up visit. To increase the response rate up to three
reminders will be sent: at 2 weeks and at 2 months after
the first contact. In the interval, non-responders will be also
telephoned to remind them that a questionnaire has been
sent and also to offer them the option to respond over the
phone if they prefer. If funding is available, the same pro-
cedure will be carried out at 5 years.
Variables
Reviewers in each hospital were provided with a handbook
with instructions to follow in the data collection process.
1. -Exposure variables:
a. Related to the patients’ personal background: date
of birth, sociodemographic variables (level of
education, occupation of the patient or of the head
of the household, marital status and living
arrangements), height, weight, lifestyle habits,
gynecological history (family history of
gynecological cancer, oral contraceptives or
hormonal replacement therapy, first and last
menstruation date, menopausal status [pre- or
postmenopausal], number of pregnancies and of births,
breastfeeding [yes/no and duration]); and comorbidities
(Charlson Comorbidity index) [16].
b. Related to the hospital: number of beds, whether
it is a teaching hospital, catchment population size,
number of patients treated for breast cancer
annually, and whether it has a breast cancer unit
and medical or radiation oncology services.
Table 2 Patients recruited by area and hospital
Region Hospital Valid
patients
Catalonia Hospital del Mar, Barcelona 97
Basque Country Hospital Galdakao-Usansolo, Bizkaia 197
Hospital de Cruces, Bizkaia 246
Hospital de Basurto, Bizkaia 125
Hospital de Txagorritxu, Araba 229
H.U. Donostia, San Sebastián, Gipuzkoa 245
Instituto Oncológico, San Sebastian, Gipuzkoa 134
Andalusia Hospital Costa del Sol, Malaga 80
Antequera, Málaga 6
Canary Islands Hospital Nuestra Sra de La Candelaria (Tenerife) 61
Hospital Universitario de Canarias (Tenerife)
Complejo Materno-Insular (Gran Canaria) 36
Clínica San Roque (Gran Canaria)
Total 1456
García-Gutierrez et al. BMC Cancer  (2018) 18:54 Page 3 of 10
c. Related to the process of care: date of first contact
with medical care (scheduled/emergency), time
between the first symptoms and the first contact
with medical services, time between the first
medical appointment and histological diagnosis,
time between diagnosis and treatment, and date
of diagnosis.
d. Related to the pre-intervention tumor history: mode
of detection (symptomatic, screen-detected),
symptoms (lump, lymph nodule, swelling or
hardening of a part of breast, change in the size
or shape of the breast, skin retraction, ulceration/
wound, pain, secretion, inflammation, nipple
retraction), date of the first symptom, clinical TNM
classification (cTNM),
additional diagnostic tests (ultrasound scan, magnetic
resonance imaging [MRI], biopsy, computerized axial
tomography [CAT], bone scan, galactography,
ultrasound), histological type (infiltrating carcinoma,
infiltrating ductal carcinoma, infiltrating lobular
carcinoma, mucinous carcinoma, metaplastic
carcinoma, intraductal carcinoma, and others) and
serum marker levels (CA15-3, CA27.9, CEA, CA125).
e. Related to neoadjuvant treatment: chemotherapy
(regimen and whether it is completed), radiotherapy,
hormone treatment, anti-HER2, and other therapies;
and clinical and radiological response (assessed by
MRI) categorized as no response (no changes or
progression), weak partial response (if the tumor
size reduced less than 50%), strong partial response
(if the tumor size reduced by 50% or more), and
complete response (no residual tumor) [17].
f. Related to surgery: date, duration of the intervention,
emergency vs scheduled, surgical technique
(quadrantectomy, lumpectomy, segmentectomy,
simple mastectomy, radical mastectomy, modified
radical mastectomy, skin-sparing mastectomy,
nipple-sparing mastectomy, contralateral
prophylactic mastectomy, lymphadenectomy),
time between diagnosis and intervention and/or
pre-surgical adjuvant treatment, and intraoperative
complications (bleeding, nerve injury, anesthetic
complications, allergic reaction to the prophylactic
antibiotic, others).
g. Related to anatomical pathology: laterality, sentinel
node biopsy (yes/no and results), histological type
(intraductal, ductal, lobular, tubular, mucinous,
medullary, cribriform, papillary, non-specific, others),
degree of differentiation, pathological TNM
(pTNM), location, size, distant metastases, vascular
and nervous infiltration, number of lymph nodes
analyzed and number positive, margin involvement,
estrogen receptor/progesterone receptor status,
Ki-67, P53, CK5/6, CK14, CK19, and HER2
expression, oncotype, and MammaPrint.
h. Related to admission: setting (hospitalization vs. or
ambulatory surgery), length of hospital stay in days
after first intervention, in-hospital complications
(seroma, wound infection, necrosis of skin flap,
pneumothorax, brachial plexus pathology, and
Fig. 1 Flow chart
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others), reintervention during admission, other
medical treatments, and death.
i. Related to follow-up: primary treatment: adjuvant
postoperative treatment (radiotherapy,
chemotherapy, hormone therapy, anti-HER2, and
other therapy), date of treatments, reconstructive
plastic surgery (yes/no, technique and date),
other postoperative treatments (rehabilitation,
psychologist/psychiatrist, others), and contact
with social services; immediate complications and
any reported during the follow-up period: chest
wall and breast complications (seroma, post-surgery
adhesions, soft tissue necrosis and recurrent skin
infections), musculoskeletal (reduced arm mobility),
lymphedema, neurological (paresthesias, neuropathy,
cognitive dysfunction), pulmonary (pneumonitis,
pulmonary fibrosis) cardiovascular morbidity
(cardiomyopathy), psychological effects (anxiety),
pain, other toxicities (ototoxicity, nephrotoxicity),
reproductive health (premature menopause,
infertility, sexual dysfunction), osteoporosis, weight
gain, mycosis, and immunosuppression
(agranulocytosis, lymphopenia); complications after
reconstructive surgery (prosthesis infection, capsular
contracture, others) and reinterventions,
readmissions, death and their respective causes;
and management of the disease during the follow-up
period: diagnostic tests after surgery (CAT, positron
emission tomography-CAT, biopsy, MRI, others),
treatments (surgery, radiotherapy, chemotherapy,
hormone therapy, anti-HER2, others), and number
of follow-up visits per year (to the surgery/
gynecology department, oncology department,
rehabilitation unit, pain unit and palliative care unit).
j. - Patient-reported measures
The EORTC-QLQ-C30 (version 3.0) [18, 19] is an
internationally validated health-related quality of life
questionnaire that is widely used in cancer research. The
core questionnaire is comprised of 30 items that assess
five functioning domains (physical, role, cognitive, emo-
tional, and social); eight cancer symptom domains
(fatigue, pain, nausea and vomiting, dyspnea, insomnia,
appetite loss, constipation, and diarrhea); financial diffi-
culties, and global quality of life. The scores are trans-
formed to a 0-100 scale, with a high score implying a
high level of functioning or global quality of life, while
for the symptom domains, higher scores indicate greater
Fig. 2 Data Collection process
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symptom burden. In conjunction with this core ques-
tionnaire (QLQ-C30), the breast cancer specific module,
EORTC-QLQ-BR23, will be used [20]. This consists of
23 items assessing disease symptoms, side effects of
treatment (surgery, chemotherapy, radiotherapy and hor-
monal treatment), body image, sexual functioning, and
future perspectives. The scoring approach is identical to
that for the QLQ-C30.
The self-complete version of the EuroQol generic health-
related quality of life questionnaire (EQ-5D) [21] consists of
two parts: the EQ-5D-5 L descriptive system and the EQ
Visual Analogue scale (EQ VAS). The descriptive system
comprises five dimensions (mobility, self-care, usual activ-
ities, pain/discomfort and anxiety/depression). Each dimen-
sion has five answer options that define different levels of
severity. The EQ VAS records respondent’s self-rated health
on a 20-mm vertical, visual analogue scale, ranging from 0
(worst imaginable health state) to 100 (best imaginable
health state).
The HADS [22, 23] is a 14-item measure that evaluates
psychological status. Seven items evaluate depression (the
HADS-D subscale) and seven evaluate anxiety (the
HADS-A subscale). A subscale score of 0 to 7 indicates
the absence of anxiety or depression; 8 to10 a possible
case of anxiety or depression; and 11 or higher a probable
case of anxiety or depression.
2. Outcomes:
a. - Objective outcomes: Second primary
malignancies, complications, recurrence
(local, regional, or remote), and death.
b. - Patient-reported outcomes: Changes in
the EORTC-QLQ-C30, EORTC-QLQ-BR23,
HADS and EQ-5D-5 L scores between
the time of inclusion in the study and
the follow-up, initially at 2 years and
then at 5 years.
Safety and ethical considerations
We have obtained permission from the European
Organization for Research and Treatment of Cancer to use
the QoL questionnaires, EORT QLQ-C30 and QLQ-BR23
and from the EuroQoL Research Foundation to use the
EQ-5D-5 L. We are using a version of HADS that has been
validated by this research group [23].
Eligible patients will be informed verbally by trained re-
search personal as well as in writing, and written informed
consent will be obtained prior to enrollment. Patients may
withdraw from the study at any time, during recruitment or
follow-up, and all data collected will be treated as confiden-
tial. All participating hospitals have staff available to answer
any questions that the patient or family members may have
about the research.
Ethics Committe of each center approved the study.
This study is registered with Clinical Trials.gov (identifier:
NCT02439554).
Follow-up
Regular follow-up visits will be performed up to 2 years at
all 13 participating hospitals. In addition, a 5-year follow-
up visit is also planned in all participating hospitals.
Sample size calculation
We estimated the sample size based on the objective
related to the creation and validation of a predictive model
for which a relatively large sample size is required. The
literature on prediction models indicates that a minimum
of 10 outcome events are needed per predictor (relapse)
[24]. Our aim is to include a limited but comprehensive
list of variables (likely, not less than 10), in the multivari-
ate regression models. Given this, we estimated that we
needed at least 100 events of the dependent variable in
the sample in order to ensure that the regression model
converges adequately. It has been reported [25] that 7% of
patients with breast cancer relapse within the first 2 years
and considering this rate, we calculated the estimated
sample size. Nevertheless, so far, based on 1456 patients,
the relapse rate has been 4%, implying that no more than
six variables should be included in the predictive models.
We included all consecutive new cases until the sample
size was achieved.
Missing data assumptions and recoding of variables
Tumor definitions:
1) Bilateral breast cancer
Bilateral tumors with different pathological diagnoses at
the time of diagnosis or up to 6 months later are described
as synchronous bilateral breast cancer, while two breast
tumors that occur in contralateral breasts at two different
time points (more than 6 months of difference) are cate-
gorized as metachronous bilateral breast cancer. Lastly,
two breast tumors with the same pathological diagnosis
are considered bilateral metastatic breast cancer.
2) A recurrence or recurrent breast cancer is breast
cancer that has come back during follow-up after
a period in which cancer had not been detected.
The cancer may come back in the same or opposite
breast or chest wall. We recorded local, regional and
metastatic recurrence.
3) A metastasis or metastatic breast cancer is defined
as disease that has spread to distant sites of the
body, such as the liver, lungs, bone, brain, and/or
other tissues or organs [26].
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Symptomatology
Data will be collected on patient pre-intervention disease-
specific symptoms.. A dichotomic variable was created
based in the presence or absence of any symptom.
Complications
A checklist (yes/no) is used for complications throughout the
course of the follow-up period (intra-surgical, during hospital
admission, and up to 2 and 5 years after the intervention,
including complications related to reconstructive surgery).
When there is no information on complications in the
medical record, it will be assumed that none occurred.
Surgical severity: We record the use of the following
surgical techniques (ranked from least to most complex):
conservative surgery (tumorectomy, quadrantectomy,
and segmentectomy), simple mastectomy, radical mast-
ectomy, modified radical mastectomy, skin-sparing
mastectomy, nipple-sparing mastectomy, areola-sparing
mastectomy, breast reconstruction and contralateral
prophylactic mastectomy.
pTNM: Staging is performed following the American Joint
Committee on Cancer [27, 28], being pTNM considered ex-
cept for cases who received neoadyuvant therapy
(cTNM).When there are no pTNM staging data, the analo-
gous cTNM will be used, otherwise, missing value will be re-
corded. In cases of bilateral cancer, we will consider the final
stage as a peak between right and left breast. In the cases of
Tx, Nx or Mx, we will consider the disease to be T0, N0 or
M0. If cM is missing, then cM will be considered to be 0.
Statistical analysis
1. - Descriptive statistics: Mean and standard
deviations for continuous variables (or median
and interquartile ranges, when the observed
variables do not follow a normal distribution) and
frequencies and percentages for qualitative variables.
2. -Bivariate analysis:The Student’s t-test or the
non-parametric Wilcoxon test (for non-normal
distributions) will be applied for two-level outcomes,
and ANOVA analysis or a Kruskal–Wallis test
(for non-normal distributions) where there are
three or more categories in the outcome.
Otherwise, for categorical variables, the Chi-square
test (or Fisher’s Exact method, where required)
will be used. Multivariate models will be used
where appropriate to adjust for confounders.
3. -Creation and validation of predicitive models:.
Participants will be randomly divided into two
groups: the derivation (60%) and validation (40%)
cohorts. The study unit will be the patient (each
patient being included only once). The predictive
model will be created with the derivation group
(group 1). Initially, univariate analyses will be
performed, to identify variables related to the
selected outcomes. Variables with a p < 0.20 will be
entered into a multivariate logistic regression model,
when outcome variables are dichotomous (mortality,
re-admissions or relapse, major complications).
Statistically significant variables will be included in
the final model. Based on its estimated contribution
in the multivariate logistic regression model, a score
will be assigned to each variable. From this, a
severity risk score will be created with the receiver
operating characteristic curve. One cut-off point
will be selected, namely, that giving the best balance
between sensitivity and specificity. For the
continuous outcomes (changes in health-related
quality of life), a general lineal model will be used.
The validity of the model and the score will be
tested in the validation sample (group 2) and also
in the retrospective sample (group 3). We will
calculate the sensitivity, specificity, and area under
the receiver operating characteristic curve (AUC),
and p values for comparisons of AUCs between the
groups. The models will be calibrated using the
Hosmer-Lemeshow test. A multilevel analysis will
be performed with patients (level 1) nested within
hospitals (level 2).
Cost analysis: The perspective of the cost analysis is that
of a public hospital in a national healthcare system, and
therefore, only direct medical costs (DMCs) will be
included. DMCs will be derived from healthcare use regis-
tered in the medical records. Data on resource use will be
obtained for the periods of 24 and 60 months after base-
line, that is, since diagnosis. This includes data on medical
visits; hospital admissions; laboratory tests, imaging stud-
ies, and other diagnostic procedures; and treatments
including surgery, medication (chemotherapy and other)
and radiotherapy. Little used and/or low cost resources
will be not considered. The value of resources used by
patients is to be calculated in terms of the relevant unit
costs and the average cost per patient in the sample. The
unit costs will be obtained for each resource from the
accounting system of participating hospitals. Unit costs
will be multiplied by the resource quantities to obtain the
annual cost for each patient. All costs will be assigned in
euros of the year in which the resource has been used; no
discount rate will be needed due to the short time horizon.
Costs will be aggregated and classified according to the
following categories: outpatient clinic visits (number of
visits to specialists); hospitalization (total length of hospital
admissions, length of stay in intensive care unit and day
hospital visits); laboratory tests (laboratory tests performed
through ambulatory care); and imaging studies (ultrasonog-
raphy, axial computerized tomography, magnetic reson-
ance, radiography and other imaging studies related to the
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diagnosis, and treatment and associated complications);
diagnostic procedures (procedures related to the monitor-
ing of the disease and associated complications); surgery
(surgical procedures related to the treatment and associated
complications); medication; radiotherapy.
Quality assurance
The reviewers will be provided with a handbook designed
by the main researchers together with clinical collabora-
tors and receive specific instructions for the identification
and collection of relevant data. During the study, they will
be also supervised by the main researcher and clinical col-
laborators. Each reviewer of each participating hospital
has an “ad hoc” database with a specific username and
password, in which all the data are to be stored. Personal
data that identify patients will be separated from the clin-
ical data and patient-reported outcomes. Patient identifi-
cation number will be used always for data management..
In addition, in each hospital there is a project manager
helping reviewers, coordinating the study and ensuring
that all processes comply with standards for good practice.
Once a month, we will assess the quality of the data col-
lection process..
Duration of the project
The project is planned to last for at least 3 years divides
in recruitment (1 year) and follow-up (2 years), At least
6 months will be required to finish error correction
process and database cleaning. In a second stage, it is
envisaged that patients will be followed-up at 5 years
after their diagnostic biopsy (but, as mentioned above,
this depends on funding).
Project management
Coordination committee responsible for all decisions is
comprised by study leaders. This study has five study
leaders, from five research groups belonging to REDIS-
SEC, who are responsible for each of the objectives. Dr.
M Sala is responsible for the general coordination as
well as the evaluation and development of predictive
models related to survival and maintenance of remission
in women with breast cancer participating in early
detection programs (interval/screening cancers). She is
coordinator of the CAMISS-Retrospective study. Dr. S
García-Gutiérrez is responsible for the objective of creating
and validating of prediction models. Dr. C Sarasqueta will
be responsible of assess outcomes and to the influence of
delays on outcomes to M Redondo. Lastly, objectives related
to economic assessment will be pursued by L García Pérez.
Discussion
Finally, 1629 patients have been recruited. The basic charac-
teristics of the sample are summarized in Table 3, stratified
by whether the women have undergone surgery.
Problems anticipated
Response rate and the difficulty of obtaining all the data
required are the main problems of this study. To reduce
the risks of low response rates and high losses to follow-
Table 3 Basic description of the participating women
Total N = 1456
Surgery No surgery
1432 (98.35%) 24 (1.65%)
Age, yearsa 57.604 (11.917) 80.575 (11.257)
Charlson comorbidity indexa 0.325 (0.752) 0.958 (1.197)
Initial treatment
Conservative 648 (45.25%) –
Simple mastectomy 203 (14.18%) –
Radical mastectomy 38 (2.65%) –
Radical modified mastectomy 46 (3.21%) –
Neoadjuvant therapy 165 (11.52%) 22 (91.67%)
Adjuvant therapy
Chemotherapy1 455 (31.77%)
ACT 166 (11.59%)
TAC 80 (5.59%)
CMF 8 (0.56%)
FEC 42 (2.93%)
FEC-Taxane 41 (2.86%)
TC 35 (2.44%)
Other 88 (6.15%)
Radiotherapy (yes) 1126 (78.63%)
Hormone therapy 1146 (80.03%)
Tamoxifen 484 (33.8%)
Tamoxifen +GnRH analogues2 50 (3.49%)
Tamoxifen +Aromatase inhibitors 12 (0.84%)
Aromatase inhibitors 639 (44.62%)
Others 26 (1.82%)
TNM3
0 135 (9.43%) 0
I 683 (47.7%) 2 (8.33%)
II 453 (31.63%) 5 (20.83%)
III 134 (9.36%) 4 (16.67%)
IV 18 (1.26%) 11 (45.83%)
1.-Chemotherapy:
ACT Adriamycin/ doxorrubicine, cyclophosphamide + taxane (docetaxel
/ paclitaxel),
TAC docetaxel, Adriamycin, cyclophosphamide,
CMF cyclophosphamide, Methotrexate 5-Fluorouracil
FAC 5-fluorouracil, Adriamycin (Doxorubicin), cyclophosphamide- FEC:
5-fluorouracil, epirubicin, cyclophosphamide
FEC-Taxane FEC + paclitaxel
TC Taxane, cyclophosphamide
2.- GnRH Gonadotropin-releasing hormone analogues
3.-pTNM pathological tumor-node-metastasis staging in patients who
underwent surgery
aMeans and, in brackets, standard deviation
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up, a great effort is done to explain patients the objectives
of the study in several times (at the enrollment and during
the follow-up visits). Questionnaires will be sent Up to
three ltimes by mail to patients and the option of complet-
ing the questionnaires over the phone is available upon re-
quest. In addition, regular contact will be maintained with
all patients. To minimize the difficulties related to data re-
trieval from health records, all reviewers have received
specific training, as well as a handbook to help them with
the follow-up process.
Expected outcomes of the study
The results of this coordinated project are expected to
generate scientifically valid and clinically and socially
important information to inform the decision-making of
managers of screening programs, the authorities respon-
sible for ensuring equality in the care process as well in
health outcomes. For clinicians, clinical prediction rules
will be developed which are expected to serve as the basis
for software applications. Our intention is to create tools
that will be easy to use, preferably to be added to elec-
tronic health records. This would allow physicians and
patients themselves to consider the individual risk at the
time of appointments, to guide their decisions. Such tools
could also be used in evaluation of health services by
health managers. Although here we describe in detail the
protocol for 2 years of follow-up, our intention is to follow
this cohort for longer (at least up to 5 years).
Dissemination of results and publication policy
REDISSEC-CAMISS (Health Services Research in Breast
Cancer) group has been established, For publication pur-
poses, an author has to have contributed to each of the fol-
lowing activities: 1) conception/design and/or analysis/
interpretation, 2) writing of the manuscript, and 3) approval
of the final version, and take public responsibility for the con-
tent of the paper. All co-authors have to review and agree
with the contents of the manuscript as submitted. Study and
manuscripts will follow the STROBE guidelines for conduct-
ing and disseminating observational studies and the TRIPOD
statement for reporting of a multivariable prediction model
for individual prognosis or diagnosis [28]. The main study re-
sults will be disseminated in the media,. The main results of
the project will also be linked to a website, created ad hoc for
this project: http://www.CaMISS.info [29].
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